Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel + pirfenidone for pancreatic cancer with liver metastasis (Phase II)
ChiCTR2000034397Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel and pirfenidone in pancreatic adenocarcinoma (PDAC) and hepatic metastasis, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate (ORR). Planned start Jul 2020; status: not yet recruiting.
02
Drugs
gemcitabinepaclitaxelpirfenidone
03
Conditions
pancreatic adenocarcinoma (PDAC)hepatic metastasis
Beyond the preview
Go deeper on ChiCTR2000034397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034397.